Imogen Pryce, COO of R&D at Relay Therapeutics, on the Dynamo Platform and Portfolio Strategy LifeSci Beat

In this episode, we chatted with Dr. Imogen Pryce, COO of R&D at Relay Therapeutics. Our conversation covered Relay Therapeutics’ scientific strategy, its unique Dynamo™ platform, and its underlying commercialization strategy and scientific differentiation.
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company that integrates disparate technologies to push drug discovery. Specifically, its Dynamo™ platform integrates leading-edge computational and experimental approaches designed to drug previously-intractable protein targets.